Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Meningococcal group A capsular polysaccharide (MenA-CPS)
- Target
- MenA-CPS
- Molecular classification
- Polysaccharide antigen, Bacterial capsule, Other
01
Overview
The Meningococcal group A capsular polysaccharide is a surface polymer unique to *Neisseria meningitidis* serogroup A, made up of O-acetylated α1→6-linked N-acetyl-D-mannosamine-1-phosphate units, with important acetate groups at position 3 and 4 introduced by CsaC acetyltransferase[1][3]. This capsule is essential for the bacterium's ability to avoid immune detection and cause disease, and its antigenic properties are exploited in vaccine formulations that provide immunity to group A meningococcal infection[3][6]. The presence and structure of this polysaccharide distinguish serogroup A from other meningococcal groups[1][2].
- Other names
- Neisseria meningitidis group A capsular polysaccharideGroup A meningococcal capsuleMenA capsular polysaccharideMenA-CPS
02
Mechanism of action
Vaccines: Induce adaptive immune response (antibody-mediated), resulting in protective immunity
03
Biological functions
Immune evasionVirulence factorAntigenicity (elicits specific antibody responses)Immune response activation (via vaccination)
04
Disease associations
Infection
05
Safety considerations
Hypersensitivity/allergic reactions to vaccine componentsRare risk of autoimmunity or adverse reactions associated with polysaccharide-based vaccinesPolysaccharide-only vaccines can be weakly immunogenic in infants and young children, but conjugate vaccines overcome this limitation
06
Interacting drugs
Meningococcal conjugate vaccine (MenAfriVac; others formulated with MenA polysaccharide)
07
Biomarkers
Anti-MenA capsular polysaccharide antibody titers (used to monitor vaccine response and efficacy in clinical studies)
Beyond the preview
Go deeper on Meningococcal group A capsular polysaccharide (MenA-CPS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal group A capsular polysaccharide (MenA-CPS).